drugset / Trial / NCT05476679
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be randomized into one of 5 treatment groups comprised of RZL-012 with or without additional study treatments:
Timeline
- Start
- 2022-09-25
- Primary completion
- 2023-06-12
- Completion
- 2023-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 200 mg | — |
| Subject | Cetirizine | Other / unclassified | 10 mg | — |
| Subject | Lidocaine | Other / unclassified | 5 ml | Other |
| Subject | Methylprednisolone | Other / unclassified | 16 mg | Oral |
| Subject | UTENPANIUM | Small molecule | 240 mg | Other |
Indications
No indication recorded.